Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.

Our latest report on the biopharmaceutical landscape analyzes industry themes, market share and concentration, ESG considerations, outlooks in the overall industry, therapeutic areas, and drug ...

Biopharmaceutical Process and Quality Consortium (BPQC) is an interdisciplinary and multi-university research collaboration based on Massachusetts BioManufacturing Center at UMass Lowell. With a close ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.